HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences’ arm inks definitive pact to acquire outstanding shares of Assertio
May-14-2026

Zydus Lifesciences’ subsidiary -- Zydus Worldwide DMCC (Zydus Worldwide) has signed a definitive agreement through its wholly owned acquisition subsidiary Zara Merger Sub Inc., (Zara) with Assertio Holdings, Inc. (Assertio), to acquire all outstanding shares of Assertio for $23.50 per share in cash representing total consideration of around $166.4 million on a fully-diluted basis, calculated using the treasury stock method. Zydus Worldwide, Zara and the company are collectively referred to as 'Zydus'.

The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions. Assertio is a U.S. based pharmaceutical company focused on specialty and oncology supportive-care therapies with its novel product ROLVEDON (eflapegrastim xnst), approved as BLA by USFDA for long-acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. The equity shares of Assertio are listed on Nasdaq with code ‘ASRT’.

This transaction has been approved by the Boards of Directors of both Zydus Worldwide and Assertio and it is structured as a tender offer to be followed by a merger, subject to customary closing conditions and regulatory approvals. This transaction will help Zydus to secure an immediate U.S. specialty oncology commercial footprint and use it as a platform to expand an oncology specialty portfolio. Assertio’s 170 plus community oncology accounts and buy-and-bill infrastructure offers a ‘ready-made’ base to build a broader oncology platform.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>